Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Psychosis, Agitation, Delirium
Interventions: ziprasidone, Standard therapy; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Clozapine, treatment as usual; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 2 more

Conditions: Treatment-resistant Schizophrenia
Interventions: Evenamide 15 mg bid, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: Schizophrenia
Interventions: RO4917838, Placebo, Standard antipsychotic therapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more

Conditions: Weight, Body
Interventions: Risperidone, Aripiprazole; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 37
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: 24 Holter Monitor Recording; Device
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions: Risperidone; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 17 Years to 35 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: Schizophrenia
Interventions: ANAVEX3-71 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Anavex Life Sciences Corp.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Schizophrenia
Interventions: Placebo, RO4917838, Antipshychotics (Standard of Care); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 27
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 23 more

Conditions: Schizophrenia
Interventions: Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Visual Decision Aid and Shared Decision Making Model, Usual Care; Behavioral
Lead sponsor: VA Nebraska Western Iowa Health Care System; Federal
Eligibility: 19 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Schizophrenia
Interventions: LY2140023, Placebo, Standard of Care; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more

Conditions: Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
Interventions: Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: CT-155, Digital Control; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 54
States / cities: Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 50 more

Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions: Lumateperone 42 mg, Risperidone 2 mg; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Post Traumatic Stress Disorder
Interventions: Quetiapine Fumarate, Standard of care meducations; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia
Interventions: LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more

Conditions: Schizophrenia
Interventions: multifamily group-adherence, multifamily group-standard; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Granada Hills, California

Conditions: Schizophrenia
Interventions: Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc); Drug
Lead sponsor: Matt Byerly; Other
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: CT-156; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Mild Traumatic Brain Injury
Interventions: Quetiapine Fumarate, TAU; Drug
Lead sponsor: Foundation for Advancing Veterans' Health Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Albuquerque, New Mexico • San Antonio, Texas

Search by objective public record fields.

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

Long-term Antipsychotic Pediatric Safety Trial

Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

A Study of ANAVEX3-71 in Adults With Schizophrenia

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization

Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury

A Long-Term, Open-Label, Study on Schizophrenia

Promoting Adherence to Treatment in Schizophrenia

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)